75 results about "Dosing drugs" patented technology

Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.

Provided herein is the use of certain biomarkers, such as tryptophan and metabolites thereof for use in certain treatment methods. Suitable tryptophan metabolites that may serve as useful biomarkers include, for example, kynurenine (Kyn), kynurenic acid (KynA), and quinolinic acid. Such biomarkers may be used in identifying a subject who may benefit from treatment, predicting the responsiveness or monitoring the response of the subject to the treatment, or determining or adjusting the dosing or dosing regimen of the treatment to the subject.

The present invention relates to an intelligent chemical phosphorus removal system for urban sewage treatment plants. A calculation model for dosing phosphorus removal agents in sewage treatment is provided. By tracking the changes of influencing factors such as the instantaneous influent flow rate, the oxidation-reduction potential in the anaerobic section, and the dissolved oxygen in the aerobic section, it is determined whether it is necessary to dose phosphorus removal agents and the dosing amount of phosphorus removal agents to achieve the standard of total phosphorus in the effluent, and a control signal is output to control the dosing pump to dose drugs as needed; the system mainly focuses on the feedback control link of chemical agents. By collecting the deviation between the orthophosphate concentration in the effluent of the secondary sedimentation tank / filter tank / membrane tank and the set target value, the dosing amount of phosphorus removal agents to be adjusted is calculated, and the frequency of the dosing pump is adjusted to achieve real-time control of the dosing amount of phosphorus removal agents.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

A pharmaceutical combination for subcutaneous administration and use thereof are provided. The pharmaceutical combination as described herein for subcutaneous administration includes a hyaluronidase and an antibody-drug conjugate. The antibody-drug conjugate includes a fragment of a bioactive molecule, and the bioactive molecule has moderate toxicity. The pharmaceutical combination can achieve a larger volume and a larger dose of administration, and the side reaction is not enhanced.

A clinical combination therapy comprising one or more pharmaceutical compositions for treating various cancers. The one or more pharmaceutical compositions include at least a first composition of an immune checkpoint inhibitor and a second composition that interacts with an extracellular matrix component of the tumor microenvironment. The first composition may, for example, include pembrolizumab, and the second composition may include an LAIR-2Fc fusion protein, such as NC410. The compositions follow a dosing and timing regimen.

The infusion packaging system with the medicine mixing function comprises an infusion container, and a combined cover structure with the medicine mixing function is connected to an opening of the infusion container in a sealed mode. The combined cover structure with the medicine mixing function comprises a protective sleeve, a puncture needle with the medicine mixing function and a combined cover. The protective sleeve is provided with an easy-to-tear line structure used for removing the protective sleeve in a segmented mode. The combined cover comprises an inner cover, the outer side of the inner cover is hermetically buckled with an outer cover, a sealing cavity is formed between the top end of the inner cover and the top end of the outer cover, and a sealing gasket is arranged in the sealing cavity; the puncture needle is arranged in the protective sleeve in a sliding mode. A combined cover structure with a medicine mixing function is adopted, and the combined cover can be welded with an infusion container into a whole to form a packaging system which is reliable in sealing. The sealing can effectively ensure that the puncture needle in the protective sleeve and the exposed area of the sealing gasket are prevented from being polluted by the outside in high-temperature steam sterilization and subsequent storage and transportation in the large-delivery medicine production process, and the safety of medicine use is ensured.

This invention discloses a wearable ultrasound delivery device for treating otitis media, comprising a wearable main body with a flexible structure adapted to the shape of the patient's ear canal, and a through-hole central channel; an ultrasound drug delivery device, detachably disposed within the central channel, comprising a drug carrier for carrying the therapeutic drug to be delivered, an ultrasound transducer assembly for providing an ultrasound-guided drug delivery mode, and a handheld controller for adjusting the millimeter-level displacement of the drug carrier into the middle ear cavity; wherein, the ultrasound transducer assembly comprises a flexible substrate and multiple piezoelectric transducer units integrated on the flexible substrate, the multiple piezoelectric transducer units constituting a phased array transducer array. This device solves the technical problems of inaccurate drug delivery, low drug delivery efficiency, inability to adapt to the ear canal structure, and complex operation in the prior art.

Ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast formulated with optimized viscosity and are suitable for intravitreal or other forms of ocular administration. The compositions can improve drug administration and absorption, distribution, metabolism, and excretion (ADME) properties. The ophthalmic pharmaceutical formulations can be administered via intravitreal injection resulting in the formation of a depot in the vitreous. The depot can remain in the vitreous for a prolonged period of time resulting in therapeutic drug levels over this period of time and improved durability.

The present invention belongs to the technical field of anorectal treatment, and particularly relates to a stacked anal nozzle for anal hemostasis and drug administration, which comprises an inner nozzle body and an outer nozzle body. The inner nozzle body is arranged inside the outer nozzle body, and a drug cavity is formed between the two. A plurality of drug holes are provided on the outer nozzle body. Through the drug holes, the drugs in the drug cavity can reach the lesion site. An insertion part conforming to the shape of the anus is provided on the outer nozzle body. First exhaust holes are correspondingly provided on the inner nozzle body and the outer nozzle body. A cap is provided at the end of the insertion part, and a second exhaust hole is provided on the cap. The first exhaust hole is communicated with the second exhaust hole. An airbag is provided on the outer edge of the cap, and the airbag is connected with an inflation tube. The present invention can ensure the single-dose drug administration, prolong the action time, has a good fitting effect between the drug and the lesion, the drug is in direct contact with the lesion, has a good action effect, remarkable curative effect, and does not affect the exhaust; it can perform hemostasis care without affecting drug administration and drug absorption, which is beneficial to shortening the treatment process and improving the treatment effect.

The utility model relates to the technical field of gynecological drug delivery structures, and discloses a gynecological drug delivery structure which comprises a drug delivery component and a drug delivery tube arranged at the front end of the drug delivery component, a vaginal dilation component is arranged on one side of the drug delivery component, a heating component is arranged on the outer side of the drug delivery component, a rotating rod is rotated, a pressing plate can be pushed to move, and a sponge body can be extruded. According to the vaginal dilation device, the movable vaginal dilation plate and the fixed vaginal dilation plate are provided with the discharge holes, so that the lubricating liquid is discharged from the discharge holes, the surface of the movable vaginal dilation plate and the surface of the fixed vaginal dilation plate are provided with the lubricating liquid respectively, the lubricating purpose can be achieved, and the discomfort caused when the movable vaginal dilation plate and the fixed vaginal dilation plate are inserted into the private part of a patient can be reduced; the threaded rod can be driven to rotate, the movable vaginal dilation plate can be driven by the sliding base to move, the movable vaginal dilation plate can be far away from the fixed vaginal dilation plate, the private part of a patient can be dilated, the push rod can push the piston to move by pressing the handle, and liquid medicine can be discharged from the medicine feeding pipe.

Provided is use of a compound represented by Formula (I), or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) in the manufacture of a medicament for treating and / or preventing an immune system disease.

The utility model provides a single medicine discharging bottle. The single medicine outlet bottle comprises a bottle body; the external threaded pipe is fixedly connected to the top end of the bottle body, and the outer surface of the external threaded pipe is in threaded connection with a bottle cap; the medicine taking tube is fixedly connected to the top end of the bottle cap, a medicine inlet is formed in the position, located at the bottom end, of the outer surface of the medicine taking tube, a rotating tube is arranged in the medicine taking tube, a medicine outlet is formed in the position, located at the bottom end, of the outer surface of the rotating tube, and a rotating disc is fixedly connected to the top end of the rotating tube. A rotating buckle is installed on the outer surface of the rotating disc, and a sealing cover is installed at the top end of the rotating disc through a rotating head. According to the single-grain medicine discharging bottle, single-grain medicine taking of the medicine bottle can be achieved each time through the structure, the probability that the medicine bottle is exposed outside and makes contact with external objects is reduced, the probability that medicine grains in the medicine bottle are polluted is reduced, and single-grain medicine taking of the medicine bottle is facilitated.

The invention relates to the technical field of sewage treatment, and discloses an automatic mixing and dosing device of a coagulation test stirrer, which comprises a box body, a circular plate is arranged at the bottom of the box body, a plurality of placing plates are uniformly arranged at the outer edge of the circular plate along the circumferential direction of the circular plate, the placing plates can be used for placing test containers, and a plurality of groups of fixing components are arranged in the circular plate. The fixing assembly is used for fixing the test container on the placing plate, a chemical adding assembly for adding chemicals into the test container is arranged in the box body, a stirring shaft is arranged right above the placing plate, stirring blades are arranged at the bottom of the stirring shaft, a stirring motor is fixedly connected to the top of the stirring shaft through a coupler, and a lifting rod is fixedly connected to the stirring motor; a lifting assembly for controlling the lifting rod to lift to lift the stirring shaft is arranged in the box body. The device can prevent the test container from sliding in the stirring process to influence the coagulation test result, realizes automatic dosing, is high in test automation degree, and has the effect of realizing all-directional automation of coagulation and stirring mixing tests.

The utility model discloses an anorectal dosing device, and belongs to the technical field of medical instruments. An anorectum drug delivery device comprises a drug delivery device body, the drug delivery device body comprises a drug storage tube, a drug storage cavity is formed in the drug storage tube, a drug delivery tube communicated with the drug storage cavity is formed at one end of the drug storage tube, the drug delivery tube is used for stretching into the anorectum of a patient, an air bag is formed at the drug delivery tube, and a driving piece penetrating through the other end of the drug storage tube is slidably arranged in the drug storage tube. A through hole communicated with the medicine storage cavity is formed in the driving piece, a connecting pipe is arranged in the through hole, one end of the connecting pipe penetrates through the medicine storage cavity to be communicated with the air bag, and the other end of the connecting pipe is connected with the inflation assembly. Through the arrangement of the air bag, the effect of fixing the dosing tube is achieved, the dosing tube is prevented from sliding or shifting in the dosing process, a certain sealing effect can be achieved on the anorectum of a patient through the expansion effect, loss of liquid medicine in the dosing process is reduced, it is ensured that medicine can make full contact with the affected part, the dosing effect is improved, and then the treatment effect is improved.

The utility model relates to a combined cover structure for an infusion container with a medicine mixing function. The combined cover structure comprises a protective sleeve, a puncture needle with the medicine mixing function and a combined cover, the first end of the protective sleeve is closed, the second end of the protective sleeve is open, the second end of the protective sleeve is buckled on the outer side of the combined cover, and an easy-to-tear line structure is arranged on the protective sleeve; the combined cover comprises an inner cover, an outer cover is buckled on the outer side of the inner cover, a sealing cavity is formed between the inner cover and the outer cover, and a sealing gasket is arranged in the sealing cavity; the puncture needle is arranged in the protective sleeve in a sliding mode and comprises a first tip and a second tip, and a channel hole is formed in the puncture needle in a penetrating mode. According to the utility model, the protective sleeve adopts an integrated structure with an easy-to-tear line structure, and the protective sleeve and the combined cover are assembled into a whole; it is effectively guaranteed that the puncture needle with the medicine mixing function in the protection sleeve and the exposed area of the sealing gasket are prevented from being polluted by the outside in the high-temperature steam sterilization in the large-infusion medicine production process and the subsequent storage and transportation process, and the safety of medicine use is guaranteed.

The invention relates to a preparation method and application of a hydrogel microneedle loaded with a glutathione storage cavery.The preparation method aims at achieving more efficient drug delivery, and according to the technical scheme, the preparation method specifically comprises the following steps that 1, a PDMS microneedle female template is prepared; 2) preparing a hydrogel microneedle material solution; 3) preparing a blank hydrogel microneedle; (4) preparing a hydrogel microneedle loaded with a glutathione storage cavern; the hydrogel microneedle loaded with the glutathione reservoir integrates the advantages of the hydrogel microneedle and the drug reservoir, the hydrogel microneedle can form a tiny channel on the skin surface, percutaneous delivery of drugs is promoted, the drug delivery efficiency is improved, the drug reservoir is carried, and the drug delivery efficiency is improved. The hydrogel microneedle has the advantages that glutathione can be prevented from being degraded due to high-temperature crosslinking and the like in the preparation process of the microneedle, the hydrogel microneedle and the glutathione reservoir are jointly applied, limitation of limited space of a microneedle body is broken through, continuous large-dose administration is realized, and the hydrogel microneedle has high percutaneous delivery efficiency.

The invention belongs to the technical field of neurobiology, and particularly relates to application of a dopamine D2 receptor G protein antagonist in preparation of a drug for treating drug addiction. Researches show that the dopamine D2 receptor G protein antagonist can inhibit recurrence after drug addiction fading induced by ignition of small-dose drugs. A mouse cocaine self-administration addiction model is adopted, a small dose of cocaine is given after model mice are subjected to regression training, and the recurrence behavior of the mouse cocaine addiction after regression is induced. A signal channel dependent on dopamine D2 receptor downstream G protein is inhibited before addiction recurrence is induced by a small dose of cocaine, and recurrence after drug-induced cocaine fading can be inhibited; however, the signal pathway for inhibiting the dependence of beta-arretin on the downstream of the dopamine D2 receptor cannot inhibit the recurrence after drug-induced cocaine fading. The invention discloses the effect of the G protein biased antagonist of the dopamine D2 receptor in treatment of drug addiction, and provides a new thought and a drug intervention target for treatment of drug addiction of cocaine and the like.

The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.

Some embodiments of the present invention include compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) of the present invention that inhibit IRAK and / or FLT3 and can be used, for example, to treat certain diseases. Some embodiments include administration and methods of using compounds of the present invention (e.g., in compositions or pharmaceutical compositions) to treat (e.g., diseases such as hematopoietic cancer, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatments using a combination of an IRAK and / or FLT3 inhibitor compound of the present invention and another therapy, such as a cancer therapy.

The present disclosure provides methods for treating ANCA-associate vasculitis in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of avacopan:or a pharmaceutically acceptable salt thereof, such that the level of plasma complement factor Bb, C3a, or C5a does not significantly change in the human upon treatment.

The embodiment of the invention relates to a convection-enhanced intracranial drug delivery method and device combining magnetic resonance and a robot. The method comprises the steps that to-be-registered three-dimensional structure image data including the brain of a target user are obtained through magnetic resonance equipment; wherein the three-dimensional structure image data comprises a target user mark point; and after the to-be-registered three-dimensional structure image data is registered, the surgical robot is controlled to move to a target position based on a planned path in a pre-generated injection plan, and an injector is controlled through an injection pump to perform injection processing according to injection information in the injection plan. Therefore, the planned injection path is determined in combination with the pre-operative personalized multi-mode image of the user, and intracranial precise micro-administration under magnetic resonance monitoring is realized under the assistance of the surgical robot.

The present application provides a method of administration that maximizes the therapeutic effect of adrenomedullin, and a drug containing adrenomedullin provided by the method of administration. The above problem is solved by providing a drug for treating a disease, which contains adrenomedullin or a derivative thereof having adrenomedullin activity, etc. as an effective ingredient, characterized in that the disease is a disease for which a therapeutic effect is expected to be obtained by administration of adrenomedullin or a derivative thereof having adrenomedullin activity, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and the effective ingredient is administered intermittently.

The tracheal catheter comprises a catheter body, an air inflation assembly, a first drug delivery assembly and a second drug delivery assembly, an air inflation opening, a first drug delivery opening and a second drug release cavity are formed in one end of the catheter body at intervals, the air inflation assembly, the first drug delivery assembly and the second drug delivery assembly are all connected with the catheter body, one end of the air inflation assembly communicates with the air inflation opening, and the other end of the air inflation assembly communicates with the second drug release cavity. One end of the first drug delivery assembly is communicated with the first drug delivery port, and the second drug delivery assembly is communicated with the second drug release cavity. By arranging the catheter body, the inflation assembly, the first drug delivery assembly and the second drug delivery assembly, it is guaranteed that an effective artificial airway is established, and the two independent drug delivery assemblies are further arranged, so that slow and continuous drug delivery can be guaranteed to conduct anti-inflammatory or anaphylactic reactions, and according to sudden diseases or special diseases, drug delivery can be conducted through the drug delivery assemblies. The medicine is accurately administrated according to needs, timely treatment is carried out, continuous treatment and emergency supplement are both considered, and the treatment effect on local mucosal inflammation and anaphylactic reaction of a patient with long-term tracheal intubation is improved.

The invention relates to a hydrogel material capable of sequentially and controllably releasing drugs as well as a preparation method and application of the hydrogel material. The biocompatibility of the hydrogel is effectively guaranteed without an exogenous cross-linking agent, and the hydrogel has good self-repairing, viscidity and integration performance and immune regulation characteristics such as acute proinflammatory and continuous anti-inflammatory properties, and is a good biological medical dressing with practical application effect for drug delivery and treatment.

The invention belongs to the technical field of medicines, and particularly relates to a high-efficiency low-toxicity anticancer combined medicine and a pharmaceutical composition. The invention provides application of guanidine compounds combined with piperlongumine in preparation of anti-cancer drugs. Wherein the guanidine compound can be selected from metformin. Compared with a single-dose drug, the combined drug provided by the invention has better anticancer activity. Compared with platinum chemotherapeutic drugs, the drug combination scheme has the same tumor killing efficacy, and has no obvious influence on mouse weight, immune system, liver function, kidney function and the like, which indicates that the toxic and side effects of the drug combination are obviously weaker than those of the platinum chemotherapeutic drugs. Therefore, the drug combination scheme provided by the invention has a very good application prospect.

The invention discloses a disassembled medicine dispensing box for an automatic medicine dispensing machine based on triggering opening of a code scanning gun, and relates to the field of automatic medicine dispensing machines, the disassembled medicine dispensing box comprises a box body with one end provided with an opening, the bottom of the box body is rotatably connected with a box cover used for sealing the opening of the box body, and a storage box used for storing disassembled medicines is arranged in the box body; a sealing cover used for sealing the storage box is fixedly connected to the box cover, and the supporting plate is connected to the interior of the storage box in a sliding mode and can stretch out of the box body in the opening direction of the box body. According to the medicine box, the sealing performance of the storage position of the disassembled medicine is effectively guaranteed, then the storage quality of the medicine is guaranteed, meanwhile, when the box body is opened, the supporting plate automatically slides out, a pharmacist can conveniently take away the medicine on the supporting plate, medicine traceability code management is implemented nationwide, the pharmacist opens the medicine box while scanning traceability codes, and the medicine box is convenient to use. The work flow is simplified, the comprehensive implementation of the drug traceability code is promoted, and the drug traceability code management is standardized.